Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events

PURPOSE: To describe serum vascular endothelial growth factor (sVEGF) in patients with neovascular age-related macular degeneration (nAMD) receiving anti-VEGF agents and associations between sVEGF and systemic serious adverse events (SSAEs). DESIGN: Exploratory analyses of a randomized controlled tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Chris A., Scott, Lauren J., Reeves, Barnaby C., Downes, Susan, Lotery, Andrew J., Dick, Andrew D., Chakravarthy, Usha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of American Academy of Ophthalmology 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278944/
https://www.ncbi.nlm.nih.gov/pubmed/30555977
http://dx.doi.org/10.1016/j.oret.2017.05.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278944/
https://www.ncbi.nlm.nih.gov/pubmed/30555977
http://dx.doi.org/10.1016/j.oret.2017.05.015

Ejemplares similares